Cargando…

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer

BACKGROUND: Antiangiogenic agents provides an optional treatment strategy for patients with metastatic breast cancer. The present study was conducted to evaluate the efficacy and safety of anlotinib as third-line or above therapy for patients with HER-2 negative metastatic breast cancer. METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Yingbo, Luo, Zhifen, Yu, Yang, He, Yaning, Liu, Chaojun, Chen, Qi, Zhu, Fangyuan, Nie, Bing, Liu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366600/ https://www.ncbi.nlm.nih.gov/pubmed/35965587 http://dx.doi.org/10.3389/fonc.2022.939343

Ejemplares similares

HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study
por: Shao, Yingbo, et al.
Publicado: (2022)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer
por: Shao, Yingbo, et al.
Publicado: (2015)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study
por: Jiang, Hong-Tao, et al.
Publicado: (2021)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study
por: Zou, Hanhui, et al.
Publicado: (2022)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
por: Agrawal, Chaturbhuj, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhang, Kun, et al.
Publicado: (2020)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
por: Yang, Jiao, et al.
Publicado: (2023)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhong, Qiuxia, et al.
Publicado: (2021)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
por: Fang, Yu, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study
por: Hong, Xinyi, et al.
Publicado: (2023)

Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
por: DeBusk, Kendra, et al.
Publicado: (2022)

The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
por: Zhang, Ren‐Shu, et al.
Publicado: (2022)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
por: Zheng, Hao-Ran, et al.
Publicado: (2022)

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer
por: Zhan, Gouling, et al.
Publicado: (2023)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary
por: Babcock, Aram, et al.
Publicado: (2020)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
por: Li, Qingqing, et al.
Publicado: (2022)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
por: Sakai, Daisuke, et al.
Publicado: (2022)

Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
por: Mehta, Sandhya, et al.
Publicado: (2023)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
por: Su, Ning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ttfm37a2ivuf1efmng3qfo3914